Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in Amyotrophic Lateral Sclerosis (ALS)
NCT07174492Phase 3Not yet recruiting
- Sponsor
- AB Science
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS), sponsored by AB Science. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
masitinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07174492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174492.